SEC Tracker
Get the app

Nautilus Biotechnology NAUT

Nautilus Biotechnology reports $234K revenue

Form
10-Q
Filed
Importance
Major
  1. Revenue: $234,000 for Q3 2026
  2. Net loss: $15.64 million for Q3 2026
  3. Diluted EPS: -$0.12 for Q3 2026
  4. Cash and equivalents: $10.47 million as of Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Nautilus Biotechnology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

1 new risk factor · 2 removed · 2 new legal mentions

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Revenue$234K$190K+23%
Net income−$15.64M−$14.47M−8.1%
Operating cash flow−$13.28M−$13.73M+3.2%
Cash$10.47M$13.17M−21%
New risk factors (1)
  • Intellectual property that we develop under government contracts and/or grants may be subject to certain government rights. +1 more paragraph
Removed risk factors (2)
  • Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.
  • Securities Act ). In addition, unless we give an Alternative Forum Consent, the federal district courts of the United States shall be the sole and exclusive forum for resolving any action asserting a claim arising under the Securities Act against any person in connection with any offering of the Company s securities…
New legal mentions (2)
  • In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. +4 more paragraphs
  • We are not currently a party to any legal proceedings that we believe, if determined adversely to us, would individually or in the aggregate have a material adverse effect on our business, financial condition or results of operations.

Similar companies

Companies of similar size in SIC 3826 and related industry codes: the same peer list as the financial tables.

  1. Sypris Solutions SYPR public float $28M, Jun 29, 2025
  2. ClearSign Technologies CLIR public float $28M, Jun 30, 2025
  3. Data I/O DAIO public float $27M, Jun 30, 2025
  4. Optex Systems Holdings OPXS public float $26M, Mar 30, 2025, over 18 months old
  5. Birchtech BCHT public float $51M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.